Effect of novel oral anticoagulants on Hospital Anxiety and Depression Scale scores

dc.contributor.authors	Cosansu, K; Ureyen, CM; Yilmaz, S;
dc.date.accessioned	2020-10-16T11:05:23Z
dc.date.available	2020-10-16T11:05:23Z
dc.date.issued	2019
dc.identifier.citation	Cosansu, K; Ureyen, CM; Yilmaz, S; (2019). Effect of novel oral anticoagulants on Hospital Anxiety and Depression Scale scores. HERZ, 44, 749-743
dc.identifier.issn	0340-9937
dc.identifier.uri	https://doi.org/10.1007/s00059-019-4828-1
dc.identifier.uri	https://hdl.handle.net/20.500.12619/69685
dc.description.abstract	Conclusion. Our study demonstrates that patients with nonvalvular AF under treatment with NOACs had lower HADS-A and HADS-D scores compared with patients on warfarin treatment. These findings suggest that NOACs may increase the quality of life and decrease morbidity and mortality by reducing anxiety and depression.
dc.language	English
dc.publisher	URBAN & VOGEL
dc.subject	Cardiovascular System & Cardiology
dc.title	Effect of novel oral anticoagulants on Hospital Anxiety and Depression Scale scores
dc.type	Article
dc.identifier.volume	44
dc.identifier.startpage	743
dc.identifier.endpage	749
dc.contributor.department	Sakarya Üniversitesi/Mühendislik Fakültesi/Metalurji Ve Malzeme Mühendisliği Bölümü
dc.contributor.saüauthor	Yılmaz, Şenol
dc.relation.journal	HERZ
dc.identifier.wos	WOS:000511609100018
dc.identifier.doi	10.1007/s00059-019-4828-1
dc.identifier.eissn	1615-6692
dc.contributor.author	K. Cosansu
dc.contributor.author	C. M. Ureyen
dc.contributor.author	Yılmaz, Şenol